Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2090-911X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer ; volume:75 ; number:1 ; day:13 ; month:2 ; year:2023 ; pages:1-9 ; date:12.2023
The Egyptian heart journal ; 75, Heft 1 (13.2.2023), 1-9, 12.2023
- Urheber
-
Levicki, Rea
Lovrić Benčić, Martina
Ivanac Vranešić, Irena
Bradić, Lada
Begovac, Marta
Jug, Juraj
Dedić Plavetić, Natalija
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43044-023-00331-y
- URN
-
urn:nbn:de:101:1-2023041609560025674903
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Levicki, Rea
- Lovrić Benčić, Martina
- Ivanac Vranešić, Irena
- Bradić, Lada
- Begovac, Marta
- Jug, Juraj
- Dedić Plavetić, Natalija
- SpringerLink (Online service)
Ähnliche Objekte (12)
Corrected QT interval and QT dispersion in temporal lobe epilepsy
Plasma homocysteine levels associated with a corrected QT interval
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Prevalence and risk factors of prolonged corrected QT interval in general Chinese population
Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Shorter course of trastuzumab: Caveat emptor
Trastuzumab administration during pregnancy: an update
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
Corrected QT interval and QT dispersion in temporal lobe epilepsy
Plasma homocysteine levels associated with a corrected QT interval
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Prevalence and risk factors of prolonged corrected QT interval in general Chinese population
Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Shorter course of trastuzumab: Caveat emptor
Trastuzumab administration during pregnancy: an update
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
Corrected QT interval and QT dispersion in temporal lobe epilepsy
Plasma homocysteine levels associated with a corrected QT interval
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Prevalence and risk factors of prolonged corrected QT interval in general Chinese population
Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Shorter course of trastuzumab: Caveat emptor
Trastuzumab administration during pregnancy: an update